Tioopo Capital announces its first exit: Oury Medical

Tioopo's first exit is in. We are proud to announce the exit of Oury Medical.

Over a three-year holding period, Oury Medical delivered approximately 20% annual growth, completed three strategic acquisitions, and built a market-leading platform in its niche. The result: a 29.2% IRR, more than 2x net for our investors in less than three years.

At Tioopo, we rely on disciplined operational value creation in SME niche sectors, not only on multiple expansion or financial engineering. Oury Medical is a clear demonstration of that approach: an investment built around real industrial capabilities, a buy-and-build strategy, and patient, hands-on work alongside founders and management.

A buy-and-build success story

Tioopo Capital first invested in Oury Guye & Fils in October 2022, a century-old French specialist in surgical instruments, alongside SPE Capital. Over the following three years, the platform was transformed through a series of add-on acquisitions into the Oury Medical group, a vertically integrated partner for surgical instrumentation serving the largest orthopedic groups in France and abroad.

The combination of operational discipline, targeted M&A, and a focused niche strategy created a business with genuine scale and durable competitive advantages, the kind of platform that attracts strong buyers.

Thank you

Congratulations to the entire Oury Medical team, to the Oury family, and to our partners. This result belongs to them as much as to us.

Our deepest thanks go to our investors, who took a chance on a different approach to private equity. This outcome is the answer we owe you, and the best is yet to come.